Eledon Pharmaceuticals Inc (ELDN) News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

Completed oversubscribed $50 million private placement First participant dosed in clinical trial at University...

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today...

Form 8-K - Current report

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to...

Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement

IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today...

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection...

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN...

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Historic kidney xenotransplantation procedure conducted at Massachusetts General Hospital Tegoprubart...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN...

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment...

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IRVINE, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN...